1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Subependymal Giant Cell Astrocytoma Global Clinical Trials Review, H1, 2015

Subependymal Giant Cell Astrocytoma Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Subependymal Giant Cell Astrocytoma Global Clinical Trials Review, H1, 2015" provides data on the Subependymal Giant Cell Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Subependymal Giant Cell Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Subependymal Giant Cell Astrocytoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Subependymal Giant Cell Astrocytoma Global Clinical Trials Review, H1, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Subependymal Giant Cell Astrocytoma 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Subependymal Giant Cell Astrocytoma to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Subependymal Giant Cell Astrocytoma to Oncology Clinical Trials 15
Clinical Trials in E7 Countries by Trial Status 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Subependymal Giant Cell Astrocytoma 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Novartis AG 26
Clinical Trial Overview of Novartis AG 26
Clinical Trial Overview of Top Institutes / Government 27
National Cancer Institute 27
Clinical Trial Overview of National Cancer Institute 27
Cincinnati Children's Hospital Medical Center 28
Clinical Trial Overview of Cincinnati Children's Hospital Medical Center 28
Societe Internationale d'Oncologie Pediatrique 29
Clinical Trial Overview of Societe Internationale d'Oncologie Pediatrique 29
Thomas Jefferson University 30
Clinical Trial Overview of Thomas Jefferson University 30
Barbara Ann Karmanos Cancer Institute 31
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 31
Five Key Clinical Profiles 32
Appendix 76
Abbreviations 76
Definitions 76
Research Methodology 77
Secondary Research 77
About GlobalData 78
Contact Us 78
Disclaimer 78
Source 79

List of Tables
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials by Region, 2015* 6
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 9
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 10
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Proportion of Subependymal Giant Cell Astrocytoma to Oncology Clinical Trials, G7 Countries (%), 2015* 12
Subependymal Giant Cell Astrocytoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Subependymal Giant Cell Astrocytoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Subependymal Giant Cell Astrocytoma to Oncology Clinical Trials, E7 Countries (%), 2015* 15
Subependymal Giant Cell Astrocytoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 16
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials by Phase, 2015* 17
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 18
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Terminated Clinical Trials, 2015* 21
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 22
Subependymal Giant Cell Astrocytoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 23
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 24
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 25
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 26
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 27
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Cincinnati Children's Hospital Medical Center, 2015* 28
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Societe Internationale d'Oncologie Pediatrique, 2015* 29
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2015* 30
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2015* 31

List of Figures
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 10
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Proportion of Subependymal Giant Cell Astrocytoma to Oncology Clinical Trials, G7 Countries (%), 2015* 12
Subependymal Giant Cell Astrocytoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Subependymal Giant Cell Astrocytoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Subependymal Giant Cell Astrocytoma to Oncology Clinical Trials, E7 Countries (%), 2015* 15
Subependymal Giant Cell Astrocytoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 16
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 17
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 18
Subependymal Giant Cell Astrocytoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 22
Subependymal Giant Cell Astrocytoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 23
Subependymal Giant Cell Astrocytoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 25
GlobalData Methodology 77

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment Summary Diabetes is a chronic metabolic disease ...

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way Summary The respiratory therapy ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.